Company and Stock Identity

How Coreline Soft Connects to the Public Market

Company structure
Public company
Market access
Direct listing: KOSDAQ: 384470.
Stock name
Coreline Soft Co., Ltd.
Ticker and exchange
KOSDAQ: 384470
Research focus
AVIEW is sold as one platform that reads several things off a single chest CT, so the question that matters is which specific finding on which specific scan a clearance actually covers. The company holds separate United States clearances for separate pieces of the range, and a clearance for lung nodule detection says nothing about the aorta measurement beside it. The second thing to check is the screening-programme business. National and workplace screening work is real revenue and a real data advantage, but it is government budget revenue, which arrives and leaves on a different schedule from hospital sales. Coreline publishes a Korean investor story and an English clinical story, and the two are not the same picture.

The company about page, read on 2026-11-14, gives the legal name Coreline Soft Co., Ltd., a founding year of 2012, and a head office at 12, Donggyo-ro 19-gil, Mapo-gu, Seoul. Its own timeline says it applied to the Korea Exchange for a preliminary KOSDAQ listing in March 2023 and was listed on the KOSDAQ in September 2023. The same page names two subsidiaries, Coreline Europe GmbH in Oberursel, Germany and Coreline North America Inc. in Suwanee, Georgia. The KOSDAQ code 384470 is carried consistently by public market data pages for the company, while the listing itself comes from the company page. No parent, acquirer or change of control is named anywhere on the site. Checked on 2026-11-14.

A current price is not available in the automated United States market snapshot. Use the named exchange or the company investor-relations page for current trading data.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Coreline Soft ... Company source

Coreline Soft gets FDA 510(k) clearance for AVIEW Aorta Metrics, adding the aorta to its chest CT reading

Coreline Soft said on 23 October 2026 that it had received United States FDA 510(k) clearance for AVIEW Aorta Metrics, and framed the decision as an expansion of the chest CT AI range it already sells in the United States. The company presents the product as automated measurement of the aorta from a chest CT rather than as a diagnosis. A 510(k) is a clearance, not an approval, and the announcement is the company stating what it now has permission to sell.

Why it matters: The commercial logic here is reuse. A hospital that already runs a chest CT for lung nodules has paid for the scan, the technologist and the patient visit, so a second measurement taken off that same scan costs almost nothing in workflow terms. That is a far easier sale than a new scan type, and it is why imaging companies keep adding findings to one platform instead of launching separate products. The caution applies to every multi-finding platform: this clearance covers the aorta measurement and is not evidence for anything else in the AVIEW range. It also does not say the measurement changes what a doctor does. Measuring something automatically and improving a decision are two different claims, and only the first one has a clearance behind it.

... Optellum ... Company source

Optellum and Coreline Soft agree to connect lung nodule detection to risk scoring in one platform

Optellum said on 13 August 2026 that it and Coreline Soft had announced an intent to collaborate, under which Optellum would integrate Coreline Soft AVIEW Lung Nodule CAD into LungOS, the Optellum platform for thoracic care. Optellum describes the Coreline Soft product as FDA cleared computer aided detection software designed to assist radiologists in detecting lung nodules, and presents the combination as connecting detection with risk assessment and care management in one workflow. Johnathan Watkins, chief executive of Optellum, is quoted calling it highly complementary to what he describes as the company position in reimbursed nodule risk assessment and management, and Jin Kook Kim, chief executive of Coreline Soft, is quoted on contributing to a more connected and scalable lung cancer care model. The announcement states an intent rather than a completed integration, and names no timetable, no financial terms and no customer.

Why it matters: This is two companies admitting they each own half of a job. Detection software tells you a nodule is there; risk software tells you how worried to be. A hospital buying them separately pays twice, integrates twice and ends up with two tools that may disagree, which is a bad position when the disagreement concerns cancer. Joining them is the obvious fix and it is genuinely useful if it happens. The words to hold onto are intent to collaborate. That is not a signed integration, not a product and not a date, and announcements at this stage sometimes go no further. Two more things stay open. Neither company has said what a hospital would pay for the combined product, and nobody has said what happens when the detection tool and the risk tool point in different directions. That handling rule is the part a radiology lead should ask about first.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The English site publishes no careers or recruitment page. Its contact page is the only route shown, and no roles are listed publicly there. What the site does show about the shape of the company is three locations: the Seoul head office, Coreline Europe GmbH in Germany and Coreline North America Inc. in Georgia. That is a regulatory, clinical research and imaging software footprint rather than a sales-only one.

Qualification signal: The experience that sets a candidate apart here is having taken an imaging algorithm through a national screening programme or a 510(k) submission, not having trained a better model. Coreline sells into government screening and into hospitals across three regions at once, so regulatory and deployment work in more than one market is the useful background. With no published careers page, treat any role you hear about as unconfirmed until the company states it directly.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

Coreline Soft appears on 2 cleared products in the federal 510(k) record, across 1 device type.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources